Second, the delayed-start design is susceptible to bias for several reasons. Of the original 1322 participants in EXPEDITION and EXPEDITION2 with mild AD, only 975 (73.8%) were enrolled in the extension phase, of whom 581 (43.9%) completed 2-year follow-up [1] . Equal drop-out percentage in both treatment groups does not rule out selection bias, when data are not missing completely at random. Furthermore, even nondifferential misclassification of outcome can introduce bias toward the 0. For the delayed-start design, this means that nondifferential misclassification suffices to have no converging of groups in the extension phase, and, thus, falsely imply noninferiority. Moreover, randomization at baseline does not prevent post-randomization confounding and selection bias [6] . For instance, use of acetylcholinesterase inhibitors during the study period may differ over time between groups, which is not accounted for by adjusting for baseline use.
Third, concerning the analyses, the authors fit mixed models to various time-points during follow-up and conclude treatment differences persisted during "much of the delayedstart period." Although the treatment differences indeed persisted up till a year, at the end of the 2-year follow-up period, differences were no longer significant and the noninferiority criteria for the primary outcome measures ADAS-Cog14 and ADCS-iADL no longer met. In any case, assessing each timepoint separately is equivalent to performing (in this case 9) interim analyses, for which correction of the P value threshold for statistical significance should be made.
Finally, none of the brain imaging markers during the EXPEDITION trials showed any difference in favor of treatment with solanezumab [2] . As these were measured to detect disease modification, discrepancy between established biomarkers of disease progression and analytical methods as the delayed-start design should be met with caution. Before considering the delayed-start design as a valid, stand-alone method for demonstrating disease modification by a treatment, we believe validation on wellestablished disease-modifying and symptomatic drugs for other conditions than AD is warranted.
Since presentation and subsequent publication of the delayed-start findings of the EXPEDITION trials [3] , media have reported this as a breakthrough in treatment for AD [7] , which has had its effects on the lay public, policy makers, even stock markets, and other stakeholders. We hope to have clarified here why this euphoria is at best premature.
